A Phase 1 interventional study of AD-234 and AD-2341 in Gastritis, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-234 compared with AD-2341, AD-2342 in healthy subjects.
135 studies on the registry are indexed under Gastritis; 23 are open to participants now.
This study's planned enrollment of 30 is below the median of 200 across 97 interventional studies indexed under Gastritis.
Browse Gastritis studies →Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
First submitted after Addpharma Inc. became part of Yuhan Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive AD-234 - AD-2341-AD-2342
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-234 - AD-2342- AD-2341
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2341-AD-234-AD-2342
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2341-AD-2342-AD-234
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2342 -AD-234-AD-2341
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2342-AD-2341-AD-234
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
AD-234 tablet administered orally
AD-2341 tablet administered orally
AD-2342 tablet administered orally
Percent of Time With Gastric pH ≥4 During the 24-hour Interval After the 7th Dose
Time frame: From pre-dose (0h) on Day 7 to 24 hours post-dose on Day 7 of each treatment period (Period 1: Day 7-Day 8; Period 2: Day 28-Day 29; Period 3: Day 49-Day 50)
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.